Your browser doesn't support javascript.
loading
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo, Giuseppe Lo; Bironzo, Paolo; Bennati, Chiara; Bonanno, Laura; Catino, Annamaria; Metro, Giulio; Petrini, Iacopo; Russano, Marco; Passaro, Antonio.
Afiliação
  • Russo GL; Medical Oncology Department, Thoracic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Bironzo P; Department of Oncology, University of Torino, Ospedale San Luigi Gonzaga, Orbassano, TO, Italy.
  • Bennati C; Department of Onco-Hematology, AUSL della Romagna, Ravenna, Italy.
  • Bonanno L; Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.
  • Catino A; Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera Perugia, Italy.
  • Petrini I; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Russano M; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milano, Italy. Electronic address: antonio.passaro@ieo.it.
Crit Rev Oncol Hematol ; 194: 104243, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38135019
ABSTRACT
Current non-small cell lung cancer (NSCLC) management relies on genome-driven precision oncology thus shifting treatment paradigm towards biomarker-guided tumor-agnostic approaches. Recently, rearranged during transfection (RET) has been endorsed as tissue-agnostic target with sensitivity to RET inhibition. There are currently two selective RET tyrosine kinase inhibitors, pralsetinib and selpercatinib. The recent introduction of pralsetinib in the treatment algorithm of RET-rearranged tumor along with the mounting clinical evidence of pralsetinib durable activity from both randomized and observational studies holds the potential to disclose new avenues in the management of RET fusion positive NSCLC patients. Our narrative review aims to discuss the available clinical evidence on pralsetinib efficacy, particularly on brain metastases, and tolerability profile. In addition, our work explores the relevance of detecting RET fusions upfront in the disease history of patients with NSCLC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Pirimidinas / Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Pirimidinas / Neoplasias Encefálicas / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article